The present invention relates to compounds of formula (I), ##STR1## wherein A is an optionally substituted phenyl naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl having at least two adjacent ring carbon atoms or a bicyclic ring system, provided that the --CH(R.sup.3)N(R.sup.2)B--R.sup.1 and --OCH(R.sup.4 --)--D linking groups arm positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the --OCHR.sup.4 -- linking group (and therefore in the 3-position relative to the --CHR.sup.3 NR.sup.2 -- linking group) is not substituted; B is an optionally substituted ring system; D is an optionally substituted ring system; R.sup.1 is a variety of group as defined in the description; R.sup.2 is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, phenylC.sub.1-3 alkyl or 5- or 6-membered heteroarylC.sub.1-3 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 is hydrogen or C.sub.1-4 alkyl; and N-oxides of NR.sup.2 where chemically possible; and S-oxides of sulphur containing rings were chemically possible; and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof. Process for their preparation, intermediates in theirpreparation, their use as therapeutic agents and pharmaceutical compositions containing them.
本发明涉及如下式(I)的化合物,其中A是一个可选择取代的苯基
萘基、
吡啶基、
吡嗪基、
吡啶啉基、
嘧啶基、
噻吩基、
噻唑基、
噁唑基、
噻二唑基,具有至少两个相邻环碳原子或双环环系统的环,前提是--CH(R^3)N(R^2)B--R^1和--OCH(R^4)--D连接基位于环碳原子上呈1,2关系,并且位于与--OCHR^4--连接基相邻的环原子(因此相对于--CHR^3 NR^2--连接基位于3位置)未被取代;B是一个可选择取代的环系统;D是一个可选择取代的环系统;R^1是描述中定义的各种基团;R^2是氢、C_1-6烷基、C_2-6烯基、C_2-6炔基、苯基C_1-3烷基或5-或6-成员的杂环基C_1-3烷基;R^3是氢或C_1-4烷基;R^4是氢或C_1-4烷基;NR^2的N-氧化物在
化学上可能;含
硫环的S-氧化物在
化学上可能;以及其药学上可接受的盐和体内可
水解的酯和酰胺。其制备方法,制备中间体,用作治疗剂的用途以及含有它们的药物组合物。